Sep 24, 2025 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – September 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral candidate, Ruvidar®, in the destruction of Herpes Simplex Virus Type 1 (“HSV-1“). The latest preclinical data was published in MDPI – Viruses titled, “Ruvidar®-An Effective Anti-Herpes Simplex Virus Agent” and is available for viewing at: Website: https://www.mdpi.com/1999-4915/17/9/1280PDF Version: https://www.mdpi.com/1999-4915/17/9/1280/pdf This peer-reviewed publication provides strong support that Ruvidar® is more effective in the treatment of HSV-1 than either Acyclovir® or Metformin®, even without light-activation. Acyclovir® and its derivatives are currently known as the gold standard treatment for HSV-1.1 According to this latest research, Acyclovir® and Metformin® had little, if any, effect on the virus, once infection … Read More

Ruvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms blocking viral binding.

A BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat cancers and infections.

Ruvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025.

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it’s lead drug formulation, Ruvidar TM , has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 (“HSV-1“) than the currently approved standard of care drug, Acyclovir. Acyclovir is an antiviral drug used to slow the growth and spread of the HSV-1 virus in the body. Acyclovir will not cure herpes, but it can lessen the symptoms of the infection. It is used to treat infections caused by herpes viruses, such … Read More

June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.

Toronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated. Supported by current Good Manufacturing Practice (“cGMP”) analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM. Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, “Theralase®’s ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the … Read More

Nov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company’s ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) (“Study II“), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025. Participants are encouraged to submit questions in advance to mperraton@theralase.com to ensure sufficient time for discussion. Zoom Meeting Link: https://us02web.zoom.us/j/81044841120Webinar ID: 810 4484 1120 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) … Read More

Nov 10, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 10, 2025) – Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company’s unaudited condensed consolidated interim 3Q2025 financial statements (“Financial Statements“). Theralase® will be hosting a conference call on Wednesday, November 19th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending September 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com. Zoom Meeting Link:   https://us02web.zoom.us/j/81044841120Webinar ID: 810 4484 1120 Conference Call in:  1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom   An archived version will be available on the website following the conference call. Financial Summary:For the nine-month period … Read More

Toronto, Ontario–(Newsfile Corp. – August 26, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company’s unaudited condensed consolidated interim 2Q2025 financial statements (“Financial Statements“). Theralase® will be hosting a conference call on Wednesday, September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending June 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com. Zoom Meeting Link: https://us02web.zoom.us/j/87203480163Webinar ID: 872 0348 0163 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom An archived version will be available on the website following the conference call. Financial Summary:For the six-month period ended June 30th: To view an … Read More